You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

September 19, 2019

Journal of Medical Device Regulation—Vietnam Chapter

Journal of Medical Device Regulation

The August 2019 edition of Global Regulatory Press’ Journal of Medical Device Regulation  features a Vietnam overview authored by two of Tilleke & Gibbins’ regulatory affair specialists in the jurisdiction—Hien Thi Thu Vu, head of the regulatory affairs team in Vietnam, and Mai Thi Le, regulatory affairs consultant in Vietnam. Their in-depth overview provides an insider’s perspective into the regulatory world

  • Market Overview: Locally manufactured medical devices vs. imported devices, and expanding medical device regulationsa
  • Legislative Framework: List of relevant legislation regulating medical devices
  • Regulatory Controls: Manufacturing and trading requirements, medical device registration and classifications, medical device importation, and advertising
  • Labeling and Language: List of compulsory content for medical device labels, and language specifications
  • Clinical Trials: Requirements for conducting clinical trials and expected timeline
  • Vigilance and Post-Market Surveillance: Traceability, and medical devices that cause of harm of post serious threats
  • Future Developments: Expected upsurge in competition as demand grows from increasing average life expectancy

To read the full Vietnam overview, please visit the Global Regulatory press website, or follow the link to the PDF below.

The regional Tilleke & Gibbins team also authored the Thailand overview for the Journal of Medical Device Regulation .

Reproduced with the kind permission of Global Regulatory Press from the Journal of Medical Device Regulation, 2019, 16(3), 35-47 (http://www.globalregulatorypress.com/).

RELATED INSIGHTS​ 

April 19, 2021
Thailand has made significant changes to its statutory interest rate framework for the first time in almost a century. Since 1925, the statutory interest rate codified in Thailand’s Civil and Commercial Code (the CCC) has remained at 7.5% per year. But with Covid-19 having an unprecedented impact on the Thai economy, the Thai Government, via emergency decree, has reduced the statutory rate. While the decree is largely aimed at providing relief to hard-hit SMEs and individual debtors, the amendments have broader implications for doing business in Thailand. Main Changes The new interest rate revisions are contained within the Emergency Decree Amending the Civil and Commercial Code B.E. 2564 (2021) (the Emergency Decree), which was published in the Government Gazette on April 10, 2021 and came into effect on April 11, 2021. The Emergency Decree amends Sections 7 and 224 of the CCC, which stated the previous statutory interest rate of 7.5% per year. The Emergency Decree makes three major changes. The first involves a reduction of the statutory interest rate from 7.5% per year to 3% per year in Section 7. The new 3% annual rate is subject to review every three years by the Ministry of Finance. The interest rate is subject to further change later by a royal decree. The second change concerns money debts under Section 224 of the CCC. The previous version of Section 224 stated, among other things, that a money debt based on a default bears interest of 7.5% per year. Under the Emergency Decree, the new actual statutory default interest rate is the statutory interest rate stated in Section 7 with an additional rate of 2% per year. The result is a 5% annual statutory default interest rate. Since the statutory default interest rate is based in part on the Section 7
March 2, 2021
The cannabis plant has fascinated many civilizations, societies, and individuals through the centuries with its unique properties, and many have learned how to benefit from these, finding a variety of therapeutic and industrial uses of the plant that, in turn, enhanced domestic economies worldwide. In Thailand, cannabis plants and their derivatives have been used since ancient times as treatment for many diseases, and the plant forms a key ingredient in many Thai traditional medicinal remedies. However, over the past few decades, cannabis usage was seen to change in a way that became incrementally more abusive, resulting in outright prohibition in almost all countries. Thailand was no exception, and in 1979 the Thai government officially enacted the Narcotics Act forbidding the use of cannabis and listing cannabis plants and their derivatives—most notably marijuana (cannabis with psychoactive properties) and hemp (cannabis with limited or no psychoactive properties)—as category 5 narcotics (i.e., prohibited substances). Despite these restrictions, many Thais continued to use cannabis illegally, and some urged the government to legalize personal and commercial use of cannabis plants and their derivatives. Eventually, some in the Thai government agreed that it was time to consider steps toward legalization, As a result, the government has been taking action to delist cannabis plants from the list of prohibited narcotics since 2018, when a regulation allowed the cultivation of hemp for industrial and non-commercial purposes, such as household cooking and research and development. The next significant step came in February 2019, when the Narcotics Act (No. 7) was amended, legalizing medical marijuana within certain limitations. In national elections the following month, the Bhumjaithai political party, whose election campaign included a pledge to decriminalize and legalize cannabis plants, won substantial support in parts of the country and chose to join the coalition government, with the Bhumjaithai party